New Market Perspective
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

New Market Perspective

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by admin November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States
next post
Stop funding the woke and the stupid

Related Posts

Trump wins Arizona to sweep swing states and...

November 10, 2024

Pentagon slammed for calling Lloyd Austin’s surgery to...

January 10, 2024

Dr. Oz young family member faints during Trump’s...

April 19, 2025

House committee to launch investigation into UN agency...

December 24, 2023

Israeli tanks roll into central Rafah for first...

May 29, 2024

First on Fox: Massive donation to Trump from...

May 16, 2024

Israel rejects UN, aid agencies criticism that Gaza...

January 23, 2024

Biden’s Meta ‘censorship’ revelations ‘vindicated’ Alito dissent in...

January 17, 2025

White House plans ‘extraordinary’ Holy Week as Trump...

April 13, 2025

Rubio introduces bill to safeguard tax-exempt groups from...

January 18, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Colombian model’s murder, just days after Mexican influencer shot on live stream, sparks condemnation of femicide

      May 19, 2025
    • Israel begins extensive Gaza ground operation after intense airstrikes kill more than 100 overnight

      May 19, 2025
    • These dragon’s blood trees exist in only one place on Earth. Now their survival is under threat

      May 19, 2025
    • Polish centrist and nationalist presidential candidates to face off in 2nd round

      May 19, 2025
    • Portugal’s ruling center-right alliance wins election, but far-right makes record gains

      May 19, 2025
    • Tanzanian opposition leader appears in court for treason trial

      May 19, 2025

    Popular

    • 1

      10 Top Oil-producing Countries (Updated 2024)

      October 19, 2024
    • 2

      Powered by rain, this seed carrier could help reforest the most remote areas

      December 19, 2023
    • 3

      A troubling theory about traders profiting from Hamas’ attack on Israel drew much attention. Why it may not be so simple.

      December 13, 2023
    • 4

      Americans are starting to feel better about the economy and inflation

      December 13, 2023
    • 5

      Rare Earths Stocks: 8 Biggest Companies in 2024

      January 12, 2024
    • 6

      Top 10 Uranium-producing Countries (Updated 2024)

      April 18, 2024
    • 7

      Investing in Graphene Companies

      May 9, 2024

    Categories

    • Business (1,322)
    • Investing (3,130)
    • Politics (4,115)
    • World (4,067)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: newmarketperspective.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 newmarketperspective.com | All Rights Reserved